利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

922 条记录 (耗时 0.023 秒)

    OFF-THE-SHELF ENGINEERED CELLS FOR THERAPY
    3.
    发明申请
    OFF-THE-SHELF ENGINEERED CELLS FOR THERAPY 审中-公开

    公开(公告)号：WO2019129850A1

    公开(公告)日：2019-07-04

    申请号：PCT/EP2018/097079

    申请日：2018-12-28

    申请人： CELLECTIS

    发明人： WILSON, Caleph ,  POIROT, Laurent ,  DUCHATEAU, Philippe

    IPC分类号： A61K39/00 ,  C12N5/00 ,  C07K16/28

    CPC分类号： A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  C07K16/2809

    摘要： The invention relates to a method for manufacturing engineered cells for therapy, comprising at least: - a supply step, wherein cells from a donor are provided; - a disruption step, wherein the cells are modified by disrupting at least one gene encoding an endogenous T Cell Receptor (TCR) component; followed by, before, after or concomitantly, - a transformation step, wherein the cells are modified by introducing at least one polynucleotide encoding a recombinant chimeric receptor into said cells followed by: - an incubation step, wherein the cells are incubated with a reagent selectively binding to an antigen present at the surface of cells expressing said endogenous TCR component, preferably binding to the alpha beta TCR. The invention also relates to a composition obtainable by this method or comprising TCR expressing cells bound to a reagent selectively binding to an antigen present at the surface of cells expressing said endogenous TCR component.

    ONCOLYTIC ADENOVIRUS ENCODING TRANSGENES
    8.
    发明申请
    ONCOLYTIC ADENOVIRUS ENCODING TRANSGENES 审中-公开
    可溶性腺病毒编码转基因

    公开(公告)号：WO2018083259A1

    公开(公告)日：2018-05-11

    申请号：PCT/EP2017/078218

    申请日：2017-11-03

    申请人： PSIOXUS THERAPEUTICS LIMITED

    发明人： BROMLEY, Alice Claire Noel ,  CHAMPION, Brian Robert

    IPC分类号： A61K35/761 ,  C07K14/52 ,  C07K14/705 ,  C07K16/28 ,  C12N15/86

    CPC分类号： C12N15/86 ,  A61K35/761 ,  C07K14/523 ,  C07K14/70532 ,  C07K16/2809 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/50 ,  C12N2710/10332 ,  C12N2710/10343

    摘要： The present disclosure relates to a replication deficient or replication capable oncolytic adenovirus, comprising: (i) a first transgene comprising a DNA sequence which encodes membrane anchored form of an immunomodulatory protein or an active fragment thereof, and (ii) at least a second transgene encoding a second protein or active fragment thereof, wherein the transgenes are located between the virus fibre gene L5 and the virus E4 gene and wherein the said transgenes are under the control of a promoter endogenous to the virus, such as the major late promoter, compositions comprising the same; and use of the virus and compositions in treatment, particularly in the treatment of cancer.

    摘要翻译： 本发明涉及具有复制缺陷或复制能力的溶瘤性腺病毒，其包含：（i）包含编码膜锚定形式的免疫调节蛋白或其活性片段的DNA序列的第一转基因，和 （ii）编码第二蛋白质或其活性片段的至少第二转基因，其中所述转基因位于病毒纤维基因L5和病毒E4基因之间，并且其中所述转基因处于病毒内源性启动子的控制下， 如主要晚期启动子，包含其的组合物; 以及将病毒和组合物用于治疗，特别是治疗癌症。